{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T05:08:01Z","timestamp":1768021681093,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05786-z","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T17:46:06Z","timestamp":1759686366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["18F-AlF-PSMA-HBED-CC as a novel tracer for the evaluation of prostate cancer patients with biochemical relapse: intraindividual comparison with 68Ga-PSMA-HBED-CC"],"prefix":"10.1007","volume":"43","author":[{"given":"Gerardo Gabriel","family":"dos Santos Loureiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Duarte Couto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Pablo","family":"Gambini Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Alonso Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"issue":"2","key":"5786_CR1","first-page":"69","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69\u201390","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"5786_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/cncr.20093","volume":"100","author":"D Khuntia","year":"2004","unstructured":"Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA (2004) Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer 100(6):1283\u20131292","journal-title":"Cancer"},{"issue":"12","key":"5786_CR3","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1007\/s00259-014-2872-x","volume":"41","author":"F Ceci","year":"2014","unstructured":"Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R et al (2014) Impact of (11)C-choline PET\/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging 41(12):2222\u20132231","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"5786_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM H\u00f6vels","year":"2008","unstructured":"H\u00f6vels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387\u2013395","journal-title":"Clin Radiol"},{"issue":"1","key":"5786_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al (2014) Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(1):11\u201320","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"5786_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Bene\u0161ov\u00e1 M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U (2016) PSMA-Targeted radionuclide therapy of metastatic Castration-Resistant prostate Cancer with 177Lu-Labeled PSMA-617. J Nucl Med 57(8):1170\u20131176","journal-title":"J Nucl Med"},{"issue":"4","key":"5786_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schom\u00e4cker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B (2015) Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate Cancer. Mol Imaging Biol 17(4):575\u2013584","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"5786_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W et al (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44(4):678\u2013688","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"5786_CR9","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-07-1517","volume":"14","author":"RC Mease","year":"2008","unstructured":"Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J et al (2008) N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L- cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin Cancer Res 14(10):3036\u20133043","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5786_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41181-018-0039-y","volume":"3","author":"J Giglio","year":"2018","unstructured":"Giglio J, Zeni M, Savio E, Engler H (2018) Synthesis of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform. EJNMMI Radiopharm Chem 3(1):4","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"6","key":"5786_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Sch\u00f6der H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K (2017) 68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44(6):1014\u20131024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5786_CR12","doi-asserted-by":"publisher","first-page":"175883592312089","DOI":"10.1177\/17588359231208960","volume":"15","author":"A Georgakopoulos","year":"2023","unstructured":"Georgakopoulos A, Bamias A, Chatziioannou S (2023) Current role of PSMA-PET imaging in the clinical management of prostate cancer. Ther Adv Med Oncol 15:17588359231208960","journal-title":"Ther Adv Med Oncol"},{"key":"5786_CR13","doi-asserted-by":"crossref","unstructured":"Souvatzoglou M, Eiber M, Martinez-Moeller A, F\u00fcrst S, Holzapfel K, Maurer T et al (2013) PET\/MR in prostate cancer: Technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging.;40(SUPPL. 1)","DOI":"10.1007\/s00259-013-2445-4"},{"issue":"4","key":"5786_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA et al (2013) Pet imaging with a [68ga]gallium-labelled Psma ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40(4):486\u2013495","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"5786_CR15","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","volume":"59","author":"FL Giesel","year":"2018","unstructured":"Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M et al (2018) Intraindividual comparison of 18 F-PSMA-1007 and 18 FDCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study. J Nucl Med 59(7):1076\u20131080","journal-title":"J Nucl Med"},{"key":"5786_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197\u2013209","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5786_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ et al (2015) Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56(5):668\u2013674","journal-title":"J Nucl Med"},{"key":"5786_CR18","doi-asserted-by":"crossref","unstructured":"Alonso O, dos Santos G, Garc\u00eda Fontes M, Balter H, Engler H (2018) 68Ga-PSMA and 11\u00a0C-Choline comparison using a tri-modality PET\/CT-MRI (3.0 T) system with a dedicated shuttle. Eur J Hybrid Imaging.;2(1)","DOI":"10.1186\/s41824-018-0027-1"},{"key":"5786_CR19","doi-asserted-by":"crossref","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T et al (2017) Prostate-specific membrane antigen ligands for imaging and therapy. Journal of Nuclear Medicine, vol 58. Society of Nuclear Medicine Inc., pp 67S\u201376S","DOI":"10.2967\/jnumed.116.186767"},{"issue":"24","key":"5786_CR20","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","volume":"17","author":"Y Chen","year":"2011","unstructured":"Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S et al (2011) 2-(3-{1-carboxy-5-[(6-[ 18F]fluoro-pyridine-3-carbonyl)-amino]- pentyl}-ureido)-pentanedioic acid, [ 18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17(24):7645\u20137653","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5786_CR21","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.118.218941","volume":"60","author":"S L\u00fctje","year":"2019","unstructured":"L\u00fctje S, Franssen GM, Herrmann K, Boerman OC, Rijpkema M, Gotthardt M, Heskamp S (2019) In vitro and in vivo characterization of an 18F-AlF-Labeled PSMA ligand for imaging of PSMA-Expressing xenografts. J Nucl Med 60(7):1017\u20131022","journal-title":"J Nucl Med"},{"key":"5786_CR22","doi-asserted-by":"publisher","first-page":"109164","DOI":"10.1016\/j.apradiso.2020.109164","volume":"161","author":"JA Ioppolo","year":"2020","unstructured":"Ioppolo JA, Nezich RA, Richardson KL, Morandeau L, Leedman PJ, Price RI (2020) Direct in vivo comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 and [18F]AlF-PSMA-11 in mice bearing PSMA-expressing xenografts. Appl Radiat Isot 161:109164","journal-title":"Appl Radiat Isot"},{"issue":"13","key":"5786_CR23","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00259-015-3118-2","volume":"42","author":"C Yu","year":"2015","unstructured":"Yu C, Pan D, Mi B, Xu Y, Lang L, Niu G et al (2015) 18 F-Alfatide II PET\/CT in healthy human volunteers and patients with brain metastases. Eur J Nucl Med Mol Imaging 42(13):2021\u20132028","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"5786_CR24","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1007\/s00259-016-3437-y","volume":"43","author":"S Boschi","year":"2016","unstructured":"Boschi S, Lee JT, Beykan S, Slavik R, Wei L, Spick C et al (2016) Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging 43(12):2122\u20132130","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5786_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1039\/C6RE00204H","volume":"2","author":"L Allott","year":"2017","unstructured":"Allott L, Da Pieve C, Turton DR, Smith G (2017) A general [18F]AlF radiochemistry procedure on two automated synthesis platforms. React Chem Eng 2(1):68\u201374","journal-title":"React Chem Eng"},{"key":"5786_CR26","doi-asserted-by":"publisher","unstructured":"EJNMMI Rep (2024) 8(1): 28.\u00a0https:\/\/doi.org\/10.1186\/s41824-024-00217-5","DOI":"10.1186\/s41824-024-00217-5"},{"issue":"5","key":"5786_CR27","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G et al (2016) Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195(5):1436\u20131443","journal-title":"J Urol"},{"issue":"2","key":"5786_CR28","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1097\/RLU.0000000000000594","volume":"40","author":"PS Chakraborty","year":"2015","unstructured":"Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C (2015) Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation. Clin Nucl Med 40(2):e163\u2013e166","journal-title":"Clin Nucl Med"},{"issue":"67","key":"5786_CR29","doi-asserted-by":"publisher","first-page":"111073","DOI":"10.18632\/oncotarget.22441","volume":"8","author":"MA Hoffmann","year":"2017","unstructured":"Hoffmann MA, Miederer M, Wieler HJ, Ruf C, Jakobs FM, Schreckenberger M (2017) Diagnostic performance of 68Gallium-PSMA-11 PET\/CT to detect significant prostate cancer and comparison with 18FEC PET\/CT. Oncotarget 8(67):111073\u2013111083","journal-title":"Oncotarget"},{"issue":"6","key":"5786_CR30","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive 68Ga-Prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and Meta-analysis. Eur Urol 70(6):926\u2013937","journal-title":"Eur Urol"},{"key":"5786_CR31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00259-016-3572-5","volume":"44","author":"C Berliner","year":"2017","unstructured":"Berliner C (2017) Detection rate of PET\/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. Eur J Nucl Med Mol Imaging 44:670\u2013677","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"5786_CR32","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.humpath.2009.06.003","volume":"40","author":"MC Haffner","year":"2009","unstructured":"Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, M\u00fchlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, Bander NH (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 40(12):1754\u20131761","journal-title":"Hum Pathol"},{"issue":"1","key":"5786_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/RLU.0000000000001871","volume":"43","author":"MR Jochumsen","year":"2018","unstructured":"Jochumsen MR, Dias AH, Bouchelouche K (2018) Benign traumatic rib fracture. Clin Nucl Med 43(1):38\u201340","journal-title":"Clin Nucl Med"},{"issue":"1","key":"5786_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00259-015-3236-x","volume":"43","author":"C Artigas","year":"2016","unstructured":"Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T et al (2016) Paget bone disease demonstrated on 68Ga-PSMA ligand PET\/CT. Eur J Nucl Med Mol Imaging 43(1):195\u2013196","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"5786_CR35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00259-014-2915-3","volume":"42","author":"T Krohn","year":"2015","unstructured":"Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A et al (2015) [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 42(2):210\u2013214","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"5786_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","volume":"69","author":"L Bud\u00e4us","year":"2016","unstructured":"Bud\u00e4us L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H et al (2016) Initial experience of 68Ga-PSMA PET\/CT imaging in High-risk prostate Cancer patients prior to radical prostatectomy. Eur Urol 69(3):393\u2013396","journal-title":"Eur Urol"},{"issue":"3","key":"5786_CR37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s11307-018-1278-8","volume":"21","author":"N Hirmas","year":"2019","unstructured":"Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J et al (2019) [68Ga]PSMA PET\/CT improves initial staging and management plan of patients with High-Risk prostate Cancer. Mol Imaging Biol 21(3):574\u2013581","journal-title":"Mol Imaging Biol"},{"key":"5786_CR38","doi-asserted-by":"crossref","unstructured":"Hope TA, Truillet CC, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ et al (2017),. Imaging response to androgen receptor inhibition using 68Ga-PSMA-11 PET: first human experience. J Nucl Med.;58(1):81\u20134.","DOI":"10.2967\/jnumed.116.181800"},{"key":"5786_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.apradiso.2017.09.003","volume":"130","author":"E Al-Momani","year":"2017","unstructured":"Al-Momani E, Israel I, Samnick S (2017) Validation of a [Al18F]PSMA-11 Preparation for clinical applications. Appl Radiat Isot 130:102\u2013108","journal-title":"Appl Radiat Isot"},{"key":"5786_CR40","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system. Am J Surg Pathol.;40(2):244\u201352","DOI":"10.1097\/PAS.0000000000000530"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05786-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:02:11Z","timestamp":1767999731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05786-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5786"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05786-z","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,5]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All human studies have been approved by the ethics committee of our Centre and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and all subsequent revisions. All persons gave their informed consent prior to their inclusion in the study. Consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"597"}}